Distinguished in Fibrolamellar Carcinoma

Dr. Daneng G. Li

Oncology
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
16 Years of Experience
Distinguished in Fibrolamellar Carcinoma
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daneng Li is an Oncologist in Duarte, California. Dr. Li has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Lymphadenectomy, and Colonoscopy.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases
Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases
Enrollment Status: Recruiting
Publish Date: March 07, 2025
Intervention Type: Other, Drug
Study Phase: Phase 1
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma
A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Biological
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 1
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Biological
Study Drug: ET140203 Autologous T Cell Product
Study Phase: Phase 1
A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lutetium Lu 177 Dotatate, Peposertib
Study Phase: Phase 1
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
Study Phase: Phase 1
Advancing Screening and Treatment for Older Patients With Cancer
Advancing Screening and Treatment for Older Patients With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)
Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)
Enrollment Status: Terminated
Publish Date: June 01, 2023
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC)
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Biological
Study Drug: ET140202 Autologous T Cell Product
Study Phase: Phase 1
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma
A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: July 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 19 Less Clinical Trials

108 Total Publications

ASO Visual Abstract: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma-Evaluation of SWOG S0809 with a Large National Database.
ASO Visual Abstract: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma-Evaluation of SWOG S0809 with a Large National Database.
Journal: Annals of surgical oncology
Published: May 17, 2025
Similar Doctors
Distinguished in Fibrolamellar Carcinoma
Dr. Anthony B. El-Khoueiry
Oncology | Hematology Oncology
Distinguished in Fibrolamellar Carcinoma
Dr. Anthony B. El-Khoueiry
Oncology | Hematology Oncology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (13.8 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony El-Khoueiry is an Oncologist and a Hematologist Oncology provider in Los Angeles, California. Dr. El-Khoueiry is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Colorectal Cancer, Liver Embolization, and Endoscopy.

Distinguished in Fibrolamellar Carcinoma
Dr. Syma U. Iqbal
Oncology | Hematology
Distinguished in Fibrolamellar Carcinoma
Dr. Syma U. Iqbal
Oncology | Hematology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (13.9 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Syma Iqbal is an Oncologist and a Hematologist in Los Angeles, California. Dr. Iqbal is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Colorectal Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Neuroendocrine Tumor, and Endoscopy.

Distinguished in Fibrolamellar Carcinoma
Dr. Saeed Sadeghi
Hematology Oncology | Hematology | Oncology
Distinguished in Fibrolamellar Carcinoma
Dr. Saeed Sadeghi
Hematology Oncology | Hematology | Oncology

The Regents Of The University Of California

200 Medical Plaza, 
Los Angeles, CA 
 (27.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Saeed Sadeghi is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Sadeghi is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Fibrolamellar Carcinoma, Liver Cancer, Schnitzler Syndrome, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 13 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile